"Cellceutix projects that an interim analysis of t
Post# of 72446
(Total Views: 644)
Posted On: 02/17/2017 9:49:47 PM
"Cellceutix projects that an interim analysis of the second cohort will be completed in approximately two weeks. The trial is anticipated to be completed in 2Q2017." That's from the recent press release, about Brilacidin-UP which had such great results with the low doses from the first cohort.
Link to that press release:
http://www.cellceutix.com/press-release/2017/...8lelciljue
It's Brilacidin-OM that will have results in 6-8 weeks:
And, after mentioning multiple big pharmas that they've talked with,
Link to that press release:
http://www.cellceutix.com/press-release/2017/...8lelciljue
It's Brilacidin-OM that will have results in 6-8 weeks:
Quote:
Interim analysis of the Phase 2 trial is expected in approximately 6 to 8 weeks. Over the next month to two months, Cellceutix expects to have interim data from both Brilacidin trials. This is particularly important for the development of Brilacidin and pursuit of partnerships as the data can provide clinical evidence of the immunomodulatory and anti-inflammatory properties of Brilacidin for indications that represent areas of unmet medical needs.
And, after mentioning multiple big pharmas that they've talked with,
Quote:
Should outcomes from ongoing clinical studies yield favorable results, the Company is optimistic that it will be able to capitalize on the data with respect to a partnership.
(4)
(0)